Kurome Therapeutics Revenue
Biotechnology Research • 
Cincinnati, Ohio, United States • 1-10 Employees
Kurome Therapeutics revenue & valuation
| Annual revenue | $600,000 |
| Revenue per employee | $150,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $2,000,000 |
| Total funding | $15,000,000 |
Key Contact at Kurome Therapeutics
Gregory Hayes
Vice President, Translational Medicine
Company overview
| Headquarters | 3536 Edwards Road Suite 100, Cincinnati, Ohio 45208, US |
| Phone number | +15134453852 |
| Websites | |
| NAICS | 541714 |
| Keywords | Oncology, Drug Development, Biomarkers, Start-Up, Diagnostics, Therapeutics, Cancer, Flt3 Inhibitors, Irak Inhibitors, Structure-Based Drug Design |
| Founded | 2019 |
| Employees | 1-10 |
| Socials |
Kurome Therapeutics Email Formats
Kurome Therapeutics uses 1 email format. The most common is {last name} (e.g., doe@kurometx.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{last name} | doe@kurometx.com | 100% |
About Kurome Therapeutics
Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms. Kurome Therapeutics is a preclinical stage company that is developing a series of IRAK1/4, panFLT3 inhibitors. Preclinical studies have demonstrated: -Broad range of efficacy in MDS and AML patient-derived cell lines -Synergy with Venclexta® (Venetoclax) to improve Venclexta® potency -Identification of a biomarker that correlates with prognosis in AML patients and maximal activation of immune signaling through this pathway in AML cells -Increased overall survival in cell line and patient-derived xenograft models, well beyond that of existing FLT3 inhibitors -Maintenance of complete efficacy even in settings of adaptive resistance to FLT3 inhibitors and in settings of FLT3 mutations Kurome Therapeutics is founded on research developed in the laboratory of Dr. Daniel Starczynowski at Cincinnati Children's Hospital Medical Center in collaboration with the National Center for Advancing Translational Sciences (NCATS) at the NIH.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Kurome Therapeutics Tech Stack
Discover the technologies and tools that power Kurome Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Security
WordPress themes
JavaScript libraries
Page builders
JavaScript libraries
Web servers
Font scripts
JavaScript libraries
Programming languages
Security
Blogs
Analytics
United Kingdom
Germany
Spain
CanadaFrequently asked questions
4.8
40,000 users
